Financhill
Sell
29

BIO Quote, Financials, Valuation and Earnings

Last price:
$230.53
Seasonality move :
-0.38%
Day range:
$227.53 - $231.99
52-week range:
$211.43 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.55x
P/B ratio:
0.94x
Volume:
648.3K
Avg. volume:
374.3K
1-year change:
-22.08%
Market cap:
$6.3B
Revenue:
$2.6B
EPS (TTM):
-$76.20

Analysts' Opinion

  • Consensus Rating
    Bio-Rad Laboratories has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $314.33, Bio-Rad Laboratories has an estimated upside of 36.39% from its current price of $230.46.
  • Price Target Downside
    According to analysts, the lowest downside price target is $245.00 representing -6.31% downside risk from its current price of $230.46.

Fair Value

  • According to the consensus of 4 analysts, Bio-Rad Laboratories has 36.39% upside to fair value with a price target of $314.33 per share.

BIO vs. S&P 500

  • Over the past 5 trading days, Bio-Rad Laboratories has overperformed the S&P 500 by 1.02% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Bio-Rad Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Bio-Rad Laboratories revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bio-Rad Laboratories reported revenues of $585.4M.

Earnings Growth

  • Bio-Rad Laboratories earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Rad Laboratories reported earnings per share of $2.29.
Enterprise value:
5.8B
EV / Invested capital:
0.74x
Price / LTM sales:
2.55x
EV / EBIT:
--
EV / Revenue:
2.29x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
17.50x
Price / Operating cash flow:
19.49x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4B
Return On Assets:
-20.89%
Net Income Margin (TTM):
-85.17%
Return On Equity:
-29.59%
Return On Invested Capital:
-25.43%
Operating Margin:
4.05%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $2.8B $2.6B $2.5B $610.8M $585.4M
Gross Profit $1.5B $1.4B $1.4B $325.9M $306M
Operating Income $390.6M $320.5M $248M $44.6M $23.7M
EBITDA -$65.5M -$247.1M -$2.5B $540.5M $133.5M
Diluted EPS -$6.43 -$10.36 -$76.20 $13.45 $2.29
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $2.2B $3.3B $3.3B $3.1B $3B
Total Assets $13.9B $14.4B $13.7B $12.6B $9.5B
Current Liabilities $609.9M $648.3M $589.6M $466.2M $506.6M
Total Liabilities $3.3B $4.2B $3.9B $3.6B $2.8B
Total Equity $10.6B $10.2B $9.8B $9.1B $6.7B
Total Debt $1.2M $1.2B $1.2B $1.2B $1.2B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $242M $346.6M $515.3M $69.8M $129.9M
Cash From Investing -$361.9M $47.6M -$114.2M -$43.1M $2.9M
Cash From Financing -$212.4M -$429.9M -$316.5M -- -$97.7M
Free Cash Flow $125.1M $185.4M $332.1M $29.6M $95.5M
BIO
Sector
Market Cap
$6.3B
$32.6M
Price % of 52-Week High
59.4%
47.07%
Dividend Yield
0%
0%
Shareholder Yield
4.46%
-0.74%
1-Year Price Total Return
-22.08%
-37.62%
Beta (5-Year)
0.932
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $228.40
200-day SMA
Sell
Level $299.35
Bollinger Bands (100)
Sell
Level 220.41 - 302.79
Chaikin Money Flow
Buy
Level 26.5M
20-day SMA
Buy
Level $227.28
Relative Strength Index (RSI14)
Sell
Level 49.32
ADX Line
Sell
Level 15.28
Williams %R
Neutral
Level -22.7522
50-day SMA
Sell
Level $235.97
MACD (12, 26)
Sell
Level -2.41
25-day Aroon Oscillator
Sell
Level -56
On Balance Volume
Neutral
Level 19.3M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.8785)
Sell
CA Score (Annual)
Level (-0.378)
Buy
Beneish M-Score (Annual)
Level (-3.6873)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.345)
Buy
Piotroski F Score (Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Stock Forecast FAQ

In the current month, BIO has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $314.33.

  • Where Will Bio-Rad Laboratories Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Bio-Rad Laboratories share price will rise to $314.33 per share over the next 12 months.

  • What Do Analysts Say About Bio-Rad Laboratories?

    Analysts are divided on their view about Bio-Rad Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories is a Sell and believe this share price will drop from its current level to $245.00.

  • What Is Bio-Rad Laboratories's Price Target?

    The price target for Bio-Rad Laboratories over the next 1-year time period is forecast to be $314.33 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is BIO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.

  • How Can I Buy Shares Of BIO?

    You can purchase shares of Bio-Rad Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories shares.

  • What Is The Bio-Rad Laboratories Share Price Today?

    Bio-Rad Laboratories was last trading at $230.53 per share. This represents the most recent stock quote for Bio-Rad Laboratories. Yesterday, Bio-Rad Laboratories closed at $230.46 per share.

  • How To Buy Bio-Rad Laboratories Stock Online?

    In order to purchase Bio-Rad Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Reddit Stock Be In 5 Years?
Where Will Reddit Stock Be In 5 Years?

On a wet March morning last year, the famously orange…

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 41x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
49
RGC alert for Jun 17

Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.

Buy
79
ARQQ alert for Jun 18

Arqit Quantum [ARQQ] is up 6.36% over the past day.

Buy
59
SYM alert for Jun 17

Symbotic [SYM] is down 3.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock